Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 892 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Comparator Condition Clear all
Completed Not applicable Interventional

Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)

NCT00329706
View directory record Official record
Conditions
Dementia
Interventions
FDG-PET brain scan
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 24, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Results available

Vascular Inflammation in Psoriasis Trial (The VIP Trial)

NCT01553058
View directory record Official record
Conditions
Psoriasis, Cardiovascular Disease
Interventions
Adalimumab (Humira), Placebo Injection, NB-UVB phototherapy
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 24, 2026, 9:14 AM EDT
Withdrawn Phase 2 Interventional

A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG

NCT01170325
View directory record Official record
Conditions
Autism, Autism Spectrum Disorders
Interventions
Divalproex Sodium, Placebo Comparator
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
3 Years to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 9:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Elders Preferences in Care Decisions

NCT01575990
View directory record Official record
Conditions
Early Detection of Cancer, Colon Cancer, Decision Making, Patient-Centered Care
Interventions
Making A Decision About CRC Screening, Drivers 65 Plus
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
70 Years to 84 Years
Enrollment
424 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 24, 2026, 9:14 AM EDT
Active, not recruiting Phase 2 Interventional

Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT05510115
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 24, 2026, 9:14 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT00829374
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo comparator
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
52
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 24, 2026, 9:14 AM EDT
Enrolling by invitation Phase 3 Interventional

A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery

NCT07832552
View directory record Official record
Conditions
Postoperative Ocular Inflammation, Postoperative Ocular Pain
Interventions
Sham (No Treatment), TRIESENCE (triamcinolone acetonide injectable suspension)
Procedure · Drug
Lead sponsor
Harrow Inc
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 24, 2026, 9:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions

NCT00864617
View directory record Official record
Conditions
Healthy
Interventions
Nifedipine Extended Release tablets 60 mg, single dose, ADALAT® CC Extended Release Tablets 60 mg
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 24, 2026, 9:14 AM EDT
Terminated Not applicable Interventional Results available

Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement

NCT02673697
View directory record Official record
Conditions
Aortic Valve Disease, Aortic Stenosis
Interventions
Perceval valve, other stented biological valve
Device
Lead sponsor
Corcym S.r.l
Industry
Eligibility
18 Years and older
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Indianapolis, Indiana • Portland, Maine • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 24, 2026, 9:14 AM EDT
Recruiting No phase listed Observational

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

NCT04846959
View directory record Official record
Conditions
Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment
Interventions
Risankizumab, Comparator
Drug
Lead sponsor
AbbVie
Industry
Eligibility
Female only
Enrollment
818 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
2
States / cities
Morrisville, North Carolina • Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 24, 2026, 9:14 AM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

NCT05124210
View directory record Official record
Conditions
COVID-19
Interventions
Sotrovimab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
0 Days to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Cullman, Alabama • Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 24, 2026, 9:14 AM EDT
Completed Not applicable Interventional Results available

Digital Knee Osteoarthritis Mindset Intervention

NCT05698368
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Mindset intervention, Active comparator
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
45 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 24, 2026, 9:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Potassium (K) and Ionized Calcium (iCa) Tests Using Capillary Specimens

NCT07287618
View directory record Official record
Conditions
Hematologic Tests
Interventions
Blood draw
Diagnostic Test
Lead sponsor
Abbott Point of Care
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Albuquerque, New Mexico • Hershey, Pennsylvania • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 24, 2026, 9:14 AM EDT
Completed Phase 2 Interventional

A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects

NCT01171313
View directory record Official record
Conditions
Parkinson's Disease
Interventions
XP21279 and carbidopa (experimental), Sinemet (comparator), Placebo for XP21279 and carbidopa, Placebo for Sinemet
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
12
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 24, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Results available

A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease

NCT01494532
View directory record Official record
Conditions
Parkinson Disease
Interventions
ropinirole/L-dopa, placebo/L-dopa
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Fountain Valley, California • Pasadena, California • Reseda, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 24, 2026, 9:14 AM EDT
Completed Phase 2 Interventional Results available

Vitamin D for Sickle-cell Respiratory Complications

NCT01443728
View directory record Official record
Conditions
Sickle Cell Disease, Vitamin D Deficiency, Acute Chest Syndrome, Asthma, Respiratory Infections
Interventions
Experimental: Vitamin D3 100,000 IU, Active Comparator: Vitamin D3 12,000 IU
Drug
Lead sponsor
Gary M Brittenham, MD
Other
Eligibility
3 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 24, 2026, 9:14 AM EDT
Recruiting Not applicable Interventional

Building Healthy Eating and Self-Esteem Together for University Students

NCT07060534
View directory record Official record
Conditions
Eating Disorders (Excluding Anorexia Nervosa), Binge-Eating Disorder
Interventions
Building Healthy Eating and Self-Esteem Together for University Students, Present-Centered Therapy
Behavioral
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lawrence, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 24, 2026, 9:14 AM EDT
Recruiting Not applicable Interventional

Implementing Contingency Management for Stimulant Use in Specialty Addiction Treatment Organizations

NCT05702021
View directory record Official record
Conditions
Stimulant Use (Diagnosis)
Interventions
Science to Service Laboratory
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Chicago, Illinois • Rockford, Illinois • Pawtucket, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 24, 2026, 9:14 AM EDT
Completed Phase 4 Interventional Results available

A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD

NCT02683265
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Aptensio XR, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 6 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Las Vegas, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 24, 2026, 9:14 AM EDT
Completed Phase 3 Interventional Results available

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

NCT01557244
View directory record Official record
Conditions
Urinary Bladder, Neurogenic
Interventions
Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin, Fesoterodine PR, Fesoterodine BIC 2 mg, Fesoterodine BIC 4 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
18
States / cities
Tucson, Arizona • Orange, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 24, 2026, 9:14 AM EDT
Active, not recruiting Not applicable Interventional Results available

Non-invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in Functional Movement Disorders

NCT05155059
View directory record Official record
Conditions
Functional Movement Disorder
Interventions
MagStim, Sham Comparator
Device · Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 9:14 AM EDT
Recruiting Not applicable Interventional

Advancing Diabetes Management for People With Physical Disabilities Optimally Through Primary Care-Based Telehealth (ADDOPT)

NCT07032844
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Digital Health Coaching, Continuous Glucose Monitoring Teleconsults
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 24, 2026, 9:14 AM EDT
Completed Not applicable Interventional Results available

Long Duration Activity and Metabolic Control After Spinal Cord Injury

NCT03139344
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Low-frequency Exercise, High-frequency Exercise
Other
Lead sponsor
Richard K Shields
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 24, 2026, 9:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy

NCT01942590
View directory record Official record
Conditions
Pompe Disease
Interventions
Clenbuterol, Placebo
Drug
Lead sponsor
Dwight Koeberl, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 24, 2026, 9:14 AM EDT